All News
Filter News
Found 73,724 articles
-
Laurent Pharmaceuticals Receives Approval from FDA to Initiate its COVID-19 Phase 2 Clinical Trial in the United States
8/27/2020
The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company's LAU-7b oral drug candidate against COVID-19 infection
-
Akers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results
8/27/2020
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice.
-
Infinitus Responds to COVID-19 Pandemic with Accelerated Digital Transformation and Greater Transparency
8/27/2020
Amidst the continued impact of COVID-19 on people around the globe, Infinitus (China) Company Ltd ("Infinitus"), a purveyor of health products and solutions, has actively adapted its business and accelerated its online initiatives to better promote its unique health philosophy and ensure transparency across production and R&D.
-
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
8/27/2020
A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled and enrollment is planned to be completed in the coming weeks
-
AEA Group Brings Medically Tested Masks to the Public in the Midst of No FDA Regulation
8/27/2020
In the US, no standards are enforced for face masks outside of the medical sector, but AEA Group LLC has stepped out to make approved, certified and tested face masks accessible online especially for the public.
-
UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence
8/27/2020
UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX ® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence Trial Did Not Meet Primary Endpoint Believed to be the Result of BOTOX Not Effectively Permeating the Urothelium RTGel Delivered Treatment to the Bladder as Expected with Dwell Time of Up to 10 Hours UroGen and AbbVie will Continue
-
Vaxart Appoints Karen J. Wilson to its Board of Directors
8/27/2020
Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced the appointment of Karen J. Wilson to its Board of Directors and as chair of its Audit Committee.
-
Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer
8/27/2020
Kymera Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, announced the appointment of Richard Chesworth, PhD, to the role of Chief Scientific Officer.
-
Aravive Strengthens Leadership Team with Appointment of Key Industry VeteransExpands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer
8/27/2020
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced the appointment of three industry veterans to its leadership team: Randy Anderson, Ph.D., Senior Vice President of Data Sciences, Elisabeth Gardiner, Ph.D., Vice President of Translational Medicine, and Patrick Simms, Vice President of Clinical Operations. “It’s a privilege and a pleasure to welcome Dr. Anderson, Dr. Gard
-
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
8/27/2020
Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease,
-
Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Annual and Special Virtual-Only Meeting
8/27/2020
Zomedica Pharmaceuticals Corp. announced that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders.
-
Relay Therapeutics Reports Second Quarter 2020 Financial Results
8/27/2020
Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, reported second quarter 2020 financial results.
-
New Data from the Interim Analysis of REGENERATE Show that OCA Helped Patients with Liver Fibrosis Due to NASH Achieve Sustained Improvement in Noninvasive Markers of Fibrosis Over Two Years of Treatment
8/27/2020
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional data indicating that obeticholic acid (OCA) helped patients with nonalcoholic steatohepatitis (NASH) achieve sustained improvements in liver biochemistry and noninvasive markers of liver fibrosis over two years of treatment.
-
SQI Diagnostics Reports Third Quarter 2020 Results
8/27/2020
SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD) (OTCQB: SQIDF), today reported its financial and operational results for the three and nine months ended June 30, 2020.
-
MANA RBM Salutes Vendor Partners Delivering Remote Trial Management and Oversight Tools: New Solutions for Adapting to the Operational Impact of COVID-19
8/27/2020
Today, MANA RBM announced the launch of new remote trial management and oversight capabilities in collaboration with select vendor partners, Bio-Optronics Inc., TransPerfect's Trial Interactive, and Integrated Clinical Systems.
-
ViewRay, GenesisCare and the University of Oxford Announce Groundbreaking Compassionate Access Programme Now Open to UK Patients with Localized Pancreatic Cancer
8/27/2020
ViewRay, the GenesisCare Foundation and the Pancreatic Cancer Research Fund Work Together to Provide MRIdian Radiation Therapy at No Cost to NHS Pancreatic Cancer Patients
-
electroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)
8/27/2020
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts1,” by Wittbrodt, Bremner et. al. in the journal Brain Stimulation.
-
Scholar Rock Announces Issuance of U.S. Patent Providing Composition of Matter Protection for SRK-015
8/27/2020
Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the United States Patent Office (USPTO) issued U.S. Patent No. 10,751,413 providing product protection for SRK-015, including composition of matter and methods of use, with an expiry of January 2037. “We are at the forefro
-
DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital International Liver Congress (EASL)
8/27/2020
DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress™ 2020 (EASL), taking place on August 27-29.
-
Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer
8/27/2020
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, announced the appointment of Robert Scala as Chief Commercial Officer.